In a pivotal Phase I/II trial of the MD Anderson Cancer Centre, 11 patients with relapsed or refractory CD19‐positive cancer (non‐Hodgkin's lymphoma or chronic lymphocytic leukaemia) were injected with UCB‐derived HLA‐mismatched anti‐CD19 CAR‐NK cells. This evidence concerns the gene CD19 and cancer.